Filing Flows › GeneDx Holdings (WGS) › Q3 2026 › vs Q2 2026
GeneDx Holdings (WGS) Q3 2026 vs Q2 2026 (quarter over quarter)
GeneDx Holdings's revenue rose $8.7M (+8%) from $114M in Q2 2026 to $123M in Q3 2026. The biggest changes: Diagnostic Test +$9.1M (+8%); Other revenue +$488K (+19%).
GeneDx Holdings, Q3 2026: revenue $123M (+5% year over year), operating margin -8.5%, net loss $12.3M, operating cash flow −$10.6M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Patients with third-party insurance | $104M | $94.7M | $9.2M | +10% |
| Institutional customers | $16.1M | $16.1M | −$37K | -0.2% |
| Diagnostic Test | $120M | $111M | $9.1M | +8% |
| Other revenue | $3.0M | $2.6M | $488K | +19% |
| Revenue | $123M | $114M | $8.7M | +8% |
| Net loss | $12.3M | $17.7M | −$5.4M | -31% |
| Costs & expenses | $135M | $133M | $2.7M | +2% |
| Operating costs | $134M | $132M | $1.6M | +1% |
| Interest & other, net | $1.9M | $803K | $1.1M | +133% |
| Income tax | $26K | −$518K | $544K | — |
| Cost of revenue | $37.0M | $36.2M | $839K | +2% |
| Research & development | $17.4M | $19.7M | −$2.3M | -12% |
| SG&A | $79.1M | $76.0M | $3.1M | +4% |
| Operating cash sources | $25.7M | $42.0M | −$16.3M | -39% |
| Depreciation & amortization | $6.9M | $6.7M | $181K | +3% |
| Share-based compensation | $8.3M | $6.3M | $1.9M | +30% |
| Cash used in operations | $10.6M | $29.0M | −$18.4M | -63% |
| Net loss absorbed | $12.3M | $17.7M | −$5.4M | -31% |
| Working capital & other | $13.4M | $24.3M | −$10.9M | -45% |
Questions
How much did GeneDx Holdings's revenue grow quarter over quarter in Q3 2026?
GeneDx Holdings's revenue rose $8.7M (+8%) from $114M in Q2 2026 to $123M in Q3 2026.
What drove GeneDx Holdings's revenue change in Q3 2026?
Diagnostic Test +$9.1M (+8%); Other revenue +$488K (+19%).